In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with
rectal cancer will be investigated. Patients with stage II or III middle/low rectal cancer
will be prospective enrolled. The total neoadjuvant therapy with the short-course
radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9
cycles will be administered. The primary endpoint is the complete response (CR) rate which
will take into account the patients with clinical and pathological complete response.